

30TH ANNIVERSARY

AMP2024
ANNUAL MEETING & EXPO

NOVEMBER 19-23, 2024
VANCOUVER
BRITISH COLUMBIA, CANADA

CORPORATE WORKSHOP PROGRAM



The Evolving Landscape of **MPOX** Public Health and Causes of Cutaneous Ulcers

This session will provide essential insights into the current mpox outbreak, highlighting why it may pose a greater threat and spread quickly to the U.S. Participants will learn about the virus's transmission, symptoms, and the significance of clade classification for effective management. Additionally, the session will cover reporting requirements for suspected cases, ensuring timely and accurate communication with state health agencies.



SPEAKER

Matthew J. Binnicker, Ph.D.

Chief Scientific Officer, Mayo Collaborative Services;
Director of the Clinical Microbiology Molecular Laboratory and
Clinical Virology Laboratory at Mayo Clinic in Rochester, MN.
Professor of Laboratory Medicine and Pathology



November 20th (Wednesday)
12:00 PM - 12:50 PM (PDT)
Lunch Provided




Room 119 & 120,
Level 1



Stop by Say Hello!
Booth #1401

CONTACT INFORMATION

Seegene USA, Inc 3 Burroughs, Irvine CA, 92618
1-800-725-2167 • info.seegeneusa@seegene.com
www.SeegeneUS.com



WELCOME TO AMP 2024 WORKSHOP DAY!

HOST COMPANIES

10x Genomics	Integrated DNA Technologies, Inc.
Abbott Molecular	Invivoscribe*
Agena Bioscience*	Labcorp
Agilent Technologies	LGC Biotech Technologies
Amgen*	LGC Clinical Diagnostics
Arima Genomics	Meridian BioScience Inc.
AstraZeneca*	NeoGenomics
Asuragen*	New England Biolabs
Autonomous Medical Devices Incorporated	Oxford Nanopore Technologies Ltd.
Biocartis	Pfizer*
Bionano Genomics*	Pillar Biosciences Inc.
Bio-Rad Laboratories, Inc.	Promega Corporation
Caris Life Sciences	Revvity
Collecta, Inc.	Roche Diagnostics Corporation*
DNAexus	Sectra
Element Biosciences	Seegene
Eli Lilly and Company*	Singular Genomics
ElitechGroup Molecular Diagnostics	SOPHiA GENETICS
EntroGen	STEMCELL Technologies Inc.
Foundation Medicine, Inc	Streck
Genomenon & CKB	Thermo Fisher Scientific*
GenomOncology	Ultima Genomics
Illumina*	Velsera*
Inflammatix	Watchmaker Genomics
Inocras	Xyall BV

Don't Miss the AMP 2024 Premier Corporate Workshop!



Fireside Chat: LDT Compliance in an Uncertain Environment

5:15 PM – 6:15 PM • 211 Level 2

Presented by: **Asuragen**

*AMP Corporate Partner Company

Disclaimer: Corporate Workshops are commercial activities. Workshop content and associated materials, including but not limited to workshop descriptions, promotional messages and handouts are the sole responsibility of the commercial entity presenting the workshop (Host Company). AMP does not endorse any commercial product or service. AMP does not review the content of commercial activities. AMP makes no warranty, express or implied, regarding any commercial product or service, and hereby disclaims, the accuracy, completeness, timeliness or merchantability or fitness for a particular purpose of the workshop content and associated materials. AMP shall not be liable for any damages, including direct, indirect, special, incidental, or consequential or any other type of damages arising out of or related to the use of the information contained in the workshop or associated materials.

CORPORATE WORKSHOPS

VANCOUVER CONVENTION CENTRE, WEST BUILDING, LEVEL 1 & 2



SCAN ME!

For the full workshop descriptions.

Or, use the AMP 2024 mobile app.



AMP 2024 CORPORATE WORKSHOP DAY SCHEDULE AT A GLANCE

TIME	TITLE	HOST	ROOM
8:00 AM			
8:00 AM – 8:50 AM	NGS Implementation Journeys: Transforming Hospital and Academic Labs into Genomic Powerhouses!	Velsera	114 & 115 Level 1
8:00 AM – 8:50 AM	Biomarker Testing in Metastatic Colorectal Cancer: BRAF Mutation Implications	Pfizer	215 & 216 Level 2
8:00 AM – 8:50 AM	Clinical Utility of Comprehensive Genomic Profiling (CGP) for Myeloid Neoplasms	NeoGenomics	111 & 112 Level 1
8:00 AM – 8:50 AM	Strategies to Drive Efficiency: Optimizing Clinical Lab Operations	Thermo Fisher Scientific	110 Level 1
8:00 AM – 8:50 AM	The Validation of the FDA Approved OncoReveal CDx Pan-Cancer Solid Tumor IVD	Pillar Biosciences Inc.	221 & 222 Level 2
8:00 AM – 8:50 AM	Transforming Heme Diagnostics: Harnessing the Power of NGS in the Evolving Landscape	Foundation Medicine, Inc	212 & 213 Level 2
8:00 AM – 8:50 AM	Treating the Tumor, Not the False Positives: Simultaneous Blood-based Molecular Profiling and Assessment of Clonal Hematopoiesis with Caris Assure	Caris Life Sciences	109 Level 1
9:00 AM			
9:00 AM – 9:50 AM	Accelerating Oncology Biomarker Interpretation from NGS Panels with CGW Plus	Velsera	114 & 115 Level 1
9:00 AM – 9:50 AM	Droplet Digital PCR (ddPCR) in Precision Oncology and MRD: Perspectives from the Trenches	Bio-Rad Laboratories, Inc.	116 & 117 Level 1
9:00 AM – 9:50 AM	Highly Multiplexed Spatial Transcriptomics in NSCLC Biomarker Discovery	10x Genomics	118 Level 1
9:00 AM – 9:50 AM	A Scalable 32 Target Multiplex RT-PCR in < 10- minutes: Designed for Point of Care Settings	Autonomous Medical Devices Incorporated	214 Level 2
9:00 AM – 9:50 AM	Impact on Clinical and Operational Outcomes: The Power of Testing Consolidation with Alinity m	Abbott Molecular	211 Level 2
9:00 AM – 9:50 AM	Key Considerations for Technical Assessment and Implementation of a New Multiplex Assay Workflow	Thermo Fisher Scientific	110 Level 1
9:00 AM – 9:50 AM	Leveraging Pillar Biosciences Targeted NGS Panels as a Rapid Front-Line Strategy to Inform and Accelerate the Delivery of Precision Medicine	Pillar Biosciences Inc.	221 & 222 Level 2
9:00 AM – 9:50 AM	Short and Long-read Sequencing Applications in Oncology and Rare Disease	New England Biolabs	220 Level 2

AMP 2024 CORPORATE WORKSHOP DAY SCHEDULE AT A GLANCE

TIME	TITLE	HOST	ROOM
9:00 AM			
9:00 AM – 9:50 AM	Optimising Outcomes in NSCLC: ctDNA Genotyping and Ultra-Fast NGS for Timely and Comprehensive Biomarker Testing at Diagnosis and at Progression	Thermo Fisher Scientific	217 - 219 Level 2
9:00 AM – 9:50 AM	Optimizing Molecular Diagnostic Assay Development for RNA Targets: Enhancing Performance and Reducing Costs	Roche	205 - 207 Level 2
9:00 AM – 9:50 AM	Scoring the GOAL: The Genomics Organization for Academic Laboratories	Integrated DNA Technologies, Inc.	119 & 120 Level 1
9:00 AM – 9:50 AM	The Paradigm Shift in Biomarker Testing to Refine mCRC Treatment Strategies	Amgen	202 - 204 Level 2
10:00 AM			
10:00 AM – 10:50 AM	Empowering Molecular Pathology Research With Fast, Flexible Sequencing and High-Throughput Spatial Multiomics	Singular Genomics	109 Level 1
10:00 AM – 10:50 AM	From Biospecimen to Biomarker: Evolving Lung Cancer Care With ctDNA Innovations Beyond Genotyping	AstraZeneca	217 - 219 Level 2
10:00 AM – 10:50 AM	Mapping the Future of Hematological Malignancy Research with OGM: Discoveries in Leukemia and Lymphomas	Bionano Genomics	215 & 216 Level 2
10:00 AM – 10:50 AM	Time- and Reagent-Optimized Approaches to Accelerate Pathogen Genomic Surveillance	New England Biolabs	220 Level 2
10:00 AM – 10:50 AM	Pharmacists' Roles in Optimizing Clinical Pharmacogenomics and Key Considerations for Laboratories Partnering with Them	Thermo Fisher Scientific	110 Level 1
10:00 AM – 10:50 AM	The Importance of Allele-Specific Copy Number Analysis in Characterizing Response to Synthetic Lethal Agents	Integrated DNA Technologies, Inc.	119 & 120 Level 1
10:00 AM – 10:50 AM	The Quest for QC Perfection: Trials, Tribulations and Test Accuracy with Patient-Like Controls	Streck	111 & 112 Level 1
10:00 AM – 10:50 AM	The Value of Internalizing FDA-Authorized Tumor Genomic Profiling Solutions for Tissue and Liquid Biopsy	Labcorp	208 & 209 Level 2
10:00 AM – 10:50 AM	Unlock the Power of CGP Testing With an Enhanced Workflow With HRD Using the AVENIO Tumor Tissue CGP Kit V2	Roche	205 - 207 Level 2
11:00 AM			
11:00 AM – 11:50 AM	OGM in Action: Transformative Insights in Sarcomas, Lymphomas, and More	Bionano Genomics	215 & 216 Level 2

AMP 2024 CORPORATE WORKSHOP DAY SCHEDULE AT A GLANCE

TIME	TITLE	HOST	ROOM
11:00 AM			
11:00 AM – 11:50 AM	A Panel Discussion on Challenges and Practice Gaps Affecting Implementation of Oncology Precision Medicine.	Illumina Bayer	212 & 213 Level 2
11:00 AM – 11:50 AM	A Streamlined Workflow to Automate Components of Hybrid Capture for Targeted Enrichment Directly on the Element AVITI Sequencer	Element Biosciences	211 Level 2
11:00 AM – 11:50 AM	ESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCR	Asuragen	114 & 115 Level 1
11:00 AM – 11:50 AM	Fast and Simple: Improving Adoption and Turnaround Time With CRCdx RAS.	EntroGen	202 - 204 Level 2
11:00 AM – 11:50 AM	Insights with Impact: Empowering Laboratories with a Decentralized MSK Solution for CGP	SOPHIA GENETICS	214 Level 2
11:00 AM – 11:50 AM	navify Mutation Profiler: Precise and Robust Tertiary Analysis of CGP Results, Featuring the Pioneering Pan-Cancer HRD Signature Score	Roche	205 - 207 Level 2
11:00 AM – 11:50 AM	Precision Oncology in Action: NGS Workflows, Multi-Site Clinical Genomic Reporting, and Organization-Wide Integration at Atrium Health	GenomOncology	221 & 222 Level 2
11:00 AM – 11:50 AM	The Emerging Role of Estrogen Receptor 1 (ESR1) Mutations and Circulating Tumor DNA Testing in Patients With Metastatic Breast Cancer	AstraZeneca	217 - 219 Level 2
11:00 AM – 11:50 AM	Unlocking Efficiency and Accuracy: Sample Extraction to Multiplex Digital PCR for Oncology Research	Thermo Fisher Scientific	110 Level 1
12:00 PM			
12:00 PM – 12:50 PM	Advancing Oncology Diagnostics: Innovative Molecular Reagents for Rapid, Accessible and Sustainable Patient-Centered Testing	Meridian BioScience	208 & 209 Level 2
12:00 PM – 12:50 PM	Clinical Scenarios Demonstrating Value of NGS Using Rapid, Targeted Panel and/or More Comprehensive Approaches for Oncology Biomarker Testing of Specimens.	Illumina	212 & 213 Level 2
12:00 PM – 12:50 PM	Identifying PIK3CA, AKT1 and PTEN-Altered HR+/HER2- Advanced Breast Cancers	AstraZeneca	217 - 219 Level 2
12:00 PM – 12:50 PM	Improving Liquid Biopsy Concordance Using Novel Reference Materials	LGC Clinical Diagnostics	220 Level 2

AMP 2024 CORPORATE WORKSHOP DAY SCHEDULE AT A GLANCE

TIME	TITLE	HOST	ROOM
12:00 PM			
12:00 PM – 12:50 PM	Long-Range PCR Meets Long-Read Sequencing: An Assay for 11 Hard-to-Decipher, High-Frequency Carrier Screening Associated Genes	Asuragen	114 & 115 Level 1
12:00 PM – 12:50 PM	Precision Pathways: Optimizing Testing Workflows for Patients with NSCLC	Eli Lilly and Company	109 Level 1
12:00 PM – 12:50 PM	Radically Simplify Your CGP and HRD Workflow With Industry-Leading Automation Using the AVENIO Tumor Tissue CGP Automated Kit	Roche	205 - 207 Level 2
12:00 PM – 12:50 PM	Revolutionizing Oncology Research: Enhancing Efficiency with Automated Nucleic Acid Extraction	Thermo Fisher Scientific	110 Level 1
12:00 PM – 12:50 PM	The Evolving Landscape of MPOX Public Health and Causes of Cutaneous Ulcers	Seegene	119 & 120 Level 1
12:00 PM – 12:50 PM	Strategic Collaborations for Expanding Liquid Biopsy Use Globally	SOPHiA GENETICS	214 Level 2
12:00 PM – 12:50 PM	Fireside Chat with Market Leaders in the Liquid Biopsy Field: Bringing MRD Testing to Clinical Practice with High-quality Large-scale Sequencing at Low Cost	Ultima Genomics	118 Level 1
12:00 PM – 12:50 PM	Utilizing Pillar Biosciences' Rapid oncoReveal 4-Gene Methylation Panel to Guide the Expanded PARPi Therapy In Breast Cancer Patients	Pillar Biosciences Inc.	111 & 112 Level 1
1:00 PM			
1:00 PM – 1:50 PM	A Simple and Accessible Workflow for Single Cell Gene Expression Profiling Using Direct Whole Blood Fixation and Immunomagnetic Cell Enrichment	STEMCELL Technologies	211 Level 2
1:00 PM – 1:50 PM	Actionable Biomarkers in Early-Stage NSCLC	Roche	205 - 207 Level 2
1:00 PM – 1:50 PM	Complete, End-to-End Genomic Profiling Solutions Leveraging Amplicon-Based NGS	Thermo Fisher Scientific	110 Level 1
1:00 PM – 1:50 PM	Discover Agilent's NGS Technologies Implemented For a Pan Cancer Liquid Biopsy and a Potential Early Detection Test for Gynecological Cancers	Agilent Technologies	215 & 216 Level 2
1:00 PM – 1:50 PM	Integrating Patient & Multi-Source Genomic Data into a Unified Clinical Care System at UAB, to Improve Research and Patient Care	GenomOncology	221 & 222 Level 2
1:00 PM – 1:50 PM	Mastering Quality Management Systems: Ensuring Compliance with the New FDA LDT Rule	Promega Corporation	202 - 204 Level 2

AMP 2024 CORPORATE WORKSHOP DAY SCHEDULE AT A GLANCE

TIME	TITLE	HOST	ROOM
1:00 PM			
1:00 PM – 1:50 PM	Practical Considerations for Integrating Enterprise-Wide Pharmacogenomics (PGX)	Illumina	212 & 213 Level 2
1:00 PM – 1:50 PM	Revolutionizing the Diagnosis of Acute Infection and Sepsis With Cutting-Edge Host Response Diagnostics With the TriVerity Test System	Inflammatix	116 & 117 Level 1
2:00 PM			
2:00 PM – 2:50 PM	Co-Development of a Laboratory Information System (LIS) for Managing Clinical Genomics Testing: from Ordering to Reporting	Sectra	220 Level 2
2:00 PM – 2:50 PM	Comprehensive Curated Content to Improve Detection and Reporting of Somatic and Germline Variants for WGS and Large Cancer Gene Panels	Genomenon	214 Level 2
2:00 PM – 2:50 PM	Expanding the Capabilities of the Laboratory by Through Precise, Sensitive, and Flexible Digital PCR	Roche	205 - 207 Level 2
2:00 PM – 2:50 PM	Harnessing Whole Genome and Transcriptome Information To Drive Innovation in Fusion and Somatic Variant Detection	Watchmaker Genomics	111 & 112 Level 1
2:00 PM – 2:50 PM	Molecular Profiling in Difficult Samples From NSCLC Quickly and Cost-Effectively	Agena Bioscience	114 & 115 Level 1
2:00 PM – 2:50 PM	Nanopore Sequencing: Advancing Human Genetics & Cancer Research	Oxford Nanopore Technologies Ltd.	109 Level 1
2:00 PM – 2:50 PM	Rapid Next-Generation Sequencing of Myeloid and Lymphoid Malignancy Samples	Thermo Fisher Scientific	110 Level 1
2:00 PM – 2:50 PM	TCR & BCR Repertoire Profiling, Functional Screens & Other Approaches for Drug Target & Biomarker Identification & Validation	Cellecta, Inc.	208 & 209 Level 2
2:00 PM – 2:50 PM	Advancing Molecular Solutions: Highly Multiplexed Assays for Central Laboratory Applications	Thermo Fisher Scientific	119 & 120 Level 1
3:00 PM			
3:00 PM – 3:50 PM	Advancing Solid Tumor Analysis: Integrating Chromosomal Microarray and Hotspot Mutation Analysis for Enhanced Diagnosis and Prognosis	Thermo Fisher Scientific	110 Level 1
3:00 PM – 3:50 PM	Aventa FusionPlus: The 3D Genomics Solution to Diagnostic Dilemmas in Solid Tumors	Arima Genomics	221 & 222 Level 2

AMP 2024 CORPORATE WORKSHOP DAY SCHEDULE AT A GLANCE

TIME	TITLE	HOST	ROOM
3:00 PM			
3:00 PM – 3:50 PM	Unlocking Cancer Insights: Advanced Tertiary Analysis with DNAnexus and Intelliseq	DNAnexus	202 - 204 Level 2
3:00 PM – 3:50 PM	Guideline-Driven PGx Testing: A New, Targeted Testing Approach Covering All AMP Tier 1 and Tier 2 Pharmacogenomic Recommendations	Agena Bioscience	114 & 115 Level 1
3:00 PM – 3:50 PM	Innovative Solutions in Nucleic Acid Extractions: Enhanced Efficiency with New Maxwell® Chemistries	Promega Corporation	116 & 117 Level 1
3:00 PM – 3:50 PM	Leveraging Highly Sensitive NGS for FLT3-ITD and NPM1 MRD Assessments in AML	Invivoscribe	215 & 216 Level 2
3:00 PM – 3:50 PM	LEX Diagnostics – The Future is 5 minute PCR	LGC Biotech Technologies	211 Level 2
3:00 PM – 3:50 PM	Overcoming Challenges in Congenital CMV Screening: Optimizing Laboratory Practices	Roche	205 - 207 Level 2
3:00 PM – 3:50 PM	Same-Day Molecular Testing Results from Cytology Specimens: The Next Frontier of Rapid On-Site Evaluation? Optimizing Small Biopsy Workflows with Idylla™	Biocartis	217 - 219 Level 2
4:00 PM			
4:00 PM – 4:50 PM	Advancing Assay Quality and Robustness in Molecular NGS Research	Revvity	118 Level 1
4:00 PM – 4:50 PM	Sensitive cfDNA Biomarker Identification by Targeted Sequencing from Plasma and Urine Samples: A Comparative Study of a Large Patient Cohort	Element Biosciences QIAGEN	214 Level 2
4:00 PM – 4:50 PM	Epitranscriptomic Insights to Enhance Molecular Analysis	Thermo Fisher Scientific	110 Level 1
4:00 PM – 4:50 PM	Unlocking Your Automated Open Channel Platform to Expand Molecular Infectious Disease Testing	ELITechGroup Molecular Diagnostics	220 Level 2
4:00 PM – 4:50 PM	Bridging the Gap Between Histopathology and Molecular Pathology by Automated Tissue Dissection for Precision Oncology	Xyall	109 Level 1
4:00 PM - 4:50 PM	Setting a New Standard in MRD Detection: Achieving Parts-per-Millions Level Sensitivity with Whole Genome Technology and ppmSeq™	Inocras	119 & 120 Level 1
5:00 PM			
5:15 PM – 6:15 PM	Fireside Chat: LDT Compliance in an Uncertain Environment	Asuragen	211 Level 2

oncoReveal™ CDx
Pan-Cancer Solid Tumor IVD

Get More Patients on Therapy. Faster.

NOW FDA APPROVED

- NGS-based companion diagnostic covering 22 clinically relevant genes
- Single-day workflow
- Sample to report <48hrs
- High sensitivity on low DNA input clinical samples
- Process up to 46 clinical specimens on a single Illumina MiSeq™ Dx Reagent Kit v3



Learn more today

PILLAR
BIOSCIENCES

Actionable answers delivered your way.

Testing solutions tailored to meet your needs.

Your Lab, Our Tests

Empowering sample and data ownership with kitted solutions for your lab



Your Tests, Our Lab

Complement comprehensive in-house solutions with guideline-driven send out tests

Join us for an innovation spotlight

Enabling access to genomic profiling through the FDA- authorized decentralized liquid biopsy solution, PGDx elio™ plasma focus Dx

Stage 2 | Thursday, Nov. 21 | 12:40 p.m.



Visit with us
Booth 1225